Novartis AG (NVS)
| Market Cap | 294.69B +35.5% |
| Revenue (ttm) | 56.67B +9.6% |
| Net Income | 13.98B +17.1% |
| EPS | 7.15 +21.8% |
| Shares Out | 1.91B |
| PE Ratio | 21.07 |
| Forward PE | 17.58 |
| Dividend | $3.08 (2.00%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 997,007 |
| Open | 156.46 |
| Previous Close | 155.06 |
| Day's Range | 153.70 - 156.46 |
| 52-Week Range | 100.49 - 170.46 |
| Beta | 0.52 |
| Analysts | Hold |
| Price Target | 144.00 (-6.52%) |
| Earnings Date | Apr 28, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $144.0, which is a decrease of -6.52% from the latest price.
News
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Basel, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This comes as publ...
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically...
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
Novartis' acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company's existing allergy portfolio. It comes just a week after Novartis announced it is acquiring...
Novartis to Buy Biotech Excellergy for Up to $2 Billion
Novartis agreed to buy Excellergy, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion
Swiss pharma company Novartis said on Friday it will acquire California-based biotech company Excellergy in a deal worth up to $2 billion.
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
– Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction...
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism desi...
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year's American Academy of Dermatology (AAD) Annual Meeting.
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potent...
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
SNV4818 is being evaluated in an early and mid-stage study for breast cancer and other advanced solid tumors, Novartis said.
Novartis to buy breast cancer drug candidate from Synnovation
Novartis said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further development ach...
Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Kα Inhibitor Program
WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology ...
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Basel, March 20, 2026 – Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a next-g...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Big drugmakers must face US overcharge claims on medications for low-income patients
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharging ...
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Basel, March 13, 2026 – Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate t...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
Basel, March 6, 2026 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1 554 shareh...
Novartis And Henrietta Lacks' Family Reach A Settlement
In this week's edition of InnovationRx, we look at the settlement between Novartis and the family of Henrietta Lacks, the startup that wants to treat Alzheimer's with microrobots, medical groups push ...
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
Amarin's results depend on a single medicine that is already facing generic competition. By contrast, Novartis has a deep lineup, plenty of growth products, and a solid dividend program.
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline Potentially unlocks multi-bill...
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending ma...
Novartis, Genentech file suit alleging illegal importation of prescription drug
Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine. The importation of the drug, which has strict shipping and...
Novartis to build radioligand therapy site in Texas to expand US manufacturing
Novartis said on Wednesday it intends to build a radioligand therapy manufacturing site in Texas, expanding its U.S. footprint with what will be its first such facility in the state and fifth nationwi...
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
Novartis' business is resilient, as evidenced by its ability to grow sales despite a major patent cliff. The Swiss healthcare giant's income program is another great attraction for long-term investors...
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton's tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spontan...